Page 1

August 12 , 2021 CITIUS PHARMA Citius Pharmaceuticals , Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update $ 115.7 million in cash and cash equivalents as of June 30 , 2021 to develop pipeline and invest in long - term growth Mino - LokⓇ Phase 3 superiority trial advancing following independent Data Monitoring Committee recommendation to proceed without any modifications CRANFORD , N.J. , Aug. 12 , 2021 / PRNewswire / -- Citius Pharmaceuticals , Inc. ( " Citius " or the " Company " ) ( Nasdaq : CTXR ) , a biopharmaceutical company dedicated to the development and commercialization of first - in - class critical care products with a focus on anti - infective products in adjunct cancer care , unique prescription products and stem cell therapy , today reported financial results for the third fiscal quarter of 2021 ended June 30 , 2021 , and provided a general business update . CITIUS PHARMA Third Fiscal Quarter 2021 and Recent Business Highlights • Received third positive recommendation from independent Data Monitoring Committee to continue the Mino - Lok® Phase 3 clinical superiority trial as planned without modifications ; no safety concerns identified ; • Characterization and expansion of NoveCite's i - MSC accession cell bank ( ACB ) underway at Waisman Biomanufacturing at the University of Wisconsin - Madison to create a cGMP master cell bank ( MCB ) ; • Received FDA guidance on proprietary Halo - Lido patient - reported outcome ( PRO ) tool ; preparing to submit an investigational new drug ( IND ) application during the fourth quarter of 2021 ; • Advanced Mino - Wrap chemistry , manufacturing and controls ( CMC ) development ;